Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) expects Phase 3 trial of Niraparib in Patients With HRD-Positive Advanced Ovarian Cancer to conclude in March 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%

Additional Information

Additional Relevant Details Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor. A Phase 1/2 monotherapy study has been completed in more than 100 patients with advanced solid tumors. Based upon the results of the Phase 1/2 study and published data from other trials of PARP inhibitors, TESARO is evaluating niraparib at a dose of 300 milligrams once daily in two Phase 3 studies.
http://www.tesarobio...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Trial, Niraparib, Ovarian Cancer, Hrd-positive Tumors, Parp Inhibitors